Last updated: July 3, 2026
ecutive summary
A sourcing plan for “dextrose 2.5% in plastic container” is defined by (1) FDA-regulated supply of sterile dextrose injection in the specified container system, (2) container material and closure compatibility for glucose solutions, (3) label and strength alignment (2.5% w/v), and (4) distribution footprint for hospital/wholesale channels. Without the destination market, strength presentation format (single-dose bag vs multidose container), and whether the container is a PVC-free solution system, a complete supplier roster cannot be produced with the required specificity.
What suppliers make dextrose 2.5% injection in plastic containers?
Featured snippet answer: Suppliers of dextrose injection are typically listed as holders and manufacturers of “Dextrose Injection, USP” at specific concentrations (including 2.5%) for IV use, supplied in common flexible plastic bag systems used by hospitals and wholesalers.
Which manufacturer types supply dextrose 2.5%?
Common supply chain roles:
- Finished dosage manufacturers: sterile manufacturing and filling into the plastic container.
- Contract sterilizers and fillers: produce and fill sterile bulk into bags under NDA/ANDA or contract manufacturing arrangements.
- Wholesaler and distributor channels: allocate product from finished-goods manufacturers to health systems.
What exact product specs change the supplier list?
Supplier availability varies by:
- Container system: flexible plastic IV bags vs other plastic containers; PVC-free vs PVC-containing systems.
- Fill format: bag size (eg, 500 mL, 1000 mL), single-dose vs other configurations.
- Labeling language: “Dextrose Injection, USP 2.5%” and any stated additives.
- Sterility and endotoxin controls: consistent with USP and FDA steriles expectations.
Which companies are the main sources of Dextrose Injection, USP 2.5%?
Featured snippet answer: The “main sources” depend on container system and packaging size, and are best validated via the drug’s FDA labeling record and the product’s listing in the FDA’s current database.
How to identify the correct supplier list
For a legally and operationally accurate supplier map, companies must be confirmed via:
- FDA’s drug labeling and approval/registration records for “Dextrose Injection, USP 2.5%”
- FDA listing that ties strength + dosage form + container to manufacturer(s)
- NDC-level mapping to the specific plastic container product
What NDC mapping is required
Two dextrose 2.5% items can share the same strength but differ in:
- NDC code
- package size
- container type
- manufacturer
Without the NDC(s), a correct “supplier list” risks mixing products that are not the same presentation.
What is the FDA status of dextrose 2.5% injection, and where do suppliers show up?
Featured snippet answer: Dextrose injection is typically marketed as an approved generic/old-and-established product with FDA-regulated labeling; suppliers are tied to drug product listings and current good manufacturing practice registrations.
How FDA listings support procurement
For supplier validation, procurement teams rely on:
- FDA drug product listing that identifies the listed manufacturer(s)
- Labeler/manufacturer relationship tied to the specific NDC(s)
Orange Book is usually not the primary tool for this category
Dextrose injection products are commonly not the focus of Orange Book exclusivity and patent analysis. The controlling lookup is typically the FDA product labeling/listing record rather than patent listings.
What generic entry risks exist for dextrose 2.5% IV solutions?
Featured snippet answer: For widely used sterile IV generics like dextrose injection, the dominant supply risk is manufacturing capacity and compliance, not typical Paragraph IV patent contests.
What drives shortages or allocation
- Sterile manufacturing line constraints
- Container supply (plastic bag film and components)
- Quality failures or deviations
- Transportation and cold-chain needs (less common for dextrose than for some biologics)
- Demand spikes from hospital formularies
What container-material issues affect suppliers of dextrose 2.5% bags?
Featured snippet answer: Container system and contact materials drive differences in manufacturer eligibility and procurement acceptance.
Common container types in the IV market
- Flexible plastic IV bags with specific polymer blends
- PVC-containing systems (less preferred in some institutional formularies)
- PVC-free systems (institutionally favored in some procurement programs)
Compatibility and administration considerations
Glucose solutions are generally compatible with standard IV bag systems, but supplier qualification is still governed by:
- USP and labeling requirements
- leachables and extractables specifications
- container integrity testing methods
How do you build a dextrose 2.5% supplier shortlist that matches the exact plastic container?
Featured snippet answer: Shortlist based on NDC-level mapping to the exact container system, then validate manufacturer identity in FDA listings and confirm packaging configuration.
Stepwise procurement mapping
- Start with the exact NDC used by your health system or wholesaler.
- Map NDC to listed manufacturer(s and labeler from FDA product listing.
- Confirm packaging attributes: bag volume, overwrap, and container material class as stated in product labeling.
- Validate distribution: availability through your contracted wholesalers.
What litigation or recalls affect dextrose 2.5% suppliers?
Featured snippet answer: For sterile IV solutions, the material risk is recall and compliance events rather than product-specific patent litigation.
How to screen suppliers for operational risk
- FDA recall notices affecting the exact NDC(s)
- FDA inspection outcomes and enforcement actions
- Recalls tied to container seal integrity, particulate matter, sterility assurance, or labeling errors
How does dextrose 2.5% compare with other dextrose concentrations for supplier availability?
Featured snippet answer: Supplier availability for dextrose injection often clusters by concentration because many manufacturers run shared bulk and filling lines; however, concentration-specific labeling and QC can still differentiate SKUs.
Why concentration and container size matter
- Different bag volumes can route through different packaging runs
- Stability and labeling processes can vary by concentration and excipient profile
Key Takeaways
- “Dextrose 2.5% in plastic container” is defined operationally by NDC, bag size, and container system, not by the concentration alone.
- A correct supplier roster requires exact NDC-level mapping to FDA-listed manufacturers for that specific plastic container presentation.
- Market risk is mostly capacity, container supply, sterility compliance, and recall history, not typical Paragraph IV patent disputes.
FAQs
- How do I confirm the listed manufacturer for dextrose 2.5% bags by NDC?
- Do PVC-free vs PVC IV bags change which manufacturers can supply dextrose 2.5%?
- What are the most common reasons for IV dextrose 2.5% shortages or allocations?
- How should hospital procurement teams compare bag volumes and NDCs for dextrose 2.5% equivalence?
- What recall categories most often affect sterile dextrose IV products?
References
- U.S. Food and Drug Administration. “Drugs@FDA: FDA Approved Drug Products.” (Accessed 2026-07-03).
- U.S. Food and Drug Administration. “NDC Directory.” (Accessed 2026-07-03).
- U.S. Food and Drug Administration. “FDA Recalls.” (Accessed 2026-07-03).
